StockIQpro
NASDAQ:VVOS

Vivos Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Vivos Therapeutics, Inc.'s revenue grew 16.0% in fiscal 2025 to $17.4M while operating margin fell to −114.1%. Free cash flow was −$17.6M, −100.9% of revenue, and the diluted share count rose 104.7%.Summary generated from Vivos Therapeutics, Inc.'s SEC filings. Latest annual report filed Apr 15, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$17.4M
Revenue growth+16.0%
Revenue, 5-yr CAGR+5.9%
Gross margin60.4%
Operating margin−114.1%
Net margin−121.4%
ROIC−24556.7%
Return on equity−655.0%
Debt / equityn/a
Free cash flow−$17.6M
FCF margin−100.9%
Share count change+104.7%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue1716141517
Operating income−20−25−17−11−20
Net income−20−24−14−11−21
Free cash flow−18−21−13−13−18

Recent filings

From SEC EDGAR

Peers

Surgical & medical instruments & apparatus